According to the results from the study conducted by Vanhersecke and colleagues [22], which evaluated the role of TLSs in samples with positive and negative PD-L1 tumors, according to a cutoff value of 1% for tumor proportion score, patients with TLS-positive tumors had response rates of 69.2% and 40.3%, considering PD-L1-positive and PD-L1-negative tumors, respectively. This evidence concerns the gene CD274 and neoplasm.